title: Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
abstract: A number of diseases are treated by passive administration of human proteins. Human coagulation factor VIII (FVIII) is one such protein which is administered to hemophilia A patients in order to manage and treat hemorrhagic incidences. This mode of therapy suffers from the side effect of generating anti-FVIII antibodies (inhibitors) which neutralizes the function of the infused FVIII. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to such a therapy. Various predisposing factors, both patient and product-related, are responsible for the development of inhibitory antibodies. A proper understanding of these "risk-factors" would eventually help to better design therapeutic regimen to tackle hemophilia A.
authors.affiliation: INSERM, UMR S 872, Les Cordeliers, Paris F-75006, France.
authors.forename: Suryasarathi
authors.initials: S
authors.lastname: Dasgupta
authors.forename: Ana-Maria
authors.initials: AM
authors.lastname: Navarrete
authors.forename: Sandrine
authors.initials: S
authors.lastname: Delignat
authors.forename: Bharath
authors.initials: B
authors.lastname: Wootla
authors.forename: Sebastien
authors.initials: S
authors.lastname: Andre
authors.forename: Valakunja
authors.initials: V
authors.lastname: Nagaraja
authors.forename: Sebastien
authors.initials: S
authors.lastname: Lacroix-Desmazes
authors.forename: Srinivas V
authors.initials: SV
authors.lastname: Kaveri
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D005169:Factor VIII / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; C078147:F8 protein, human; D005169:Factor VIII